Kaplan-Meier survival analysis in the TCGA cohort indicated that the NSCLC patients harboring high mRNA levels of angiogenesis-related genes (including ANGPTL4, FN1, HSPG2, and SRPX2) have poorer prognosis, suggesting that those patients may be unsuitable for anlotinib therapy. The gene discussed is ANGPTL4; the disease is non-small cell lung carcinoma.